Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors at 2 institutions in 1 country.
Ashley L CunninghamDepartment of Molecular Biosciences, University of Texas at Austin, Austin, Texas, USA.
Orhi Esarte PalomeroDepartment of Molecular Biosciences, University of Texas at Austin, Austin, Texas, USA.
Bradley J VossDepartment of Infectious Diseases, The University of Georgia, College of Veterinary Medicine, Athens, Georgia, USA.
M Stephen TrentDepartment of Infectious Diseases, The University of Georgia, College of Veterinary Medicine, Athens, Georgia, USA.ORCID 0000-0001-6134-1800
Bryan W DaviesDepartment of Molecular Biosciences, University of Texas at Austin, Austin, Texas, USA.ORCID 0000-0002-2046-0341
The University of Texas at Austin · USGeorgia College & State University · US
Funding
The Cell Envelope of the Multi-Drug Resistant Pathogen Acinetobacter baumanniiR01AI150098 · NIAID · UNIVERSITY OF GEORGIA · PI Michael Stephen Trent · 2020 to 2026
$3.9M
Development of a novel vaccine platform: Surface Antigen/Adjuvant Vaccine Engineering (SAAVE)R01AI129940 · NIAID · UNIVERSITY OF GEORGIA · PI TRENT, MICHAEL STEPHEN · 2017 to 2021
$3.3M
Investigating nanobodies to target multidrug resistant bacterial pathogensR01AI148419 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI DAVIES, BRYAN WILLIAM · 2020 to 2023
$2.8M
Molecular mechanisms required for the maintenance of the gram-negative outer membraneR01AI138576 · NIAID · UNIVERSITY OF GEORGIA · PI TRENT, MICHAEL STEPHEN · 2018 to 2022
$2.0M
A High-Throughput Molecular Platform for Antimicrobial Discovery and StudyR01AI125337 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI DAVIES, BRYAN WILLIAM · 2016 to 2020
$2.0M
Investigation of capsule interactions that promote antimicrobial peptide activityR21AI159203 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI DAVIES, BRYAN WILLIAM · 2021 to 2022
$429k
Investigation of the lipid transport Mla pathwayF32GM125264 · NIGMS · UNIVERSITY OF GEORGIA · PI VOSS, BRADLEY JACOB · 2017 to 2019
Otilonium bromide is a poorly absorbed oral medication used to control irritable bowel syndrome. It is thought to act as a muscle relaxant in the intestine. Here, we show that otilonium bromide has broad-spectrum antibacterial and antifungal activity, including against multidrug-resistant strains. Our results suggest otilonium bromide acts on enteric pathogens and may offer a new scaffold for poorly absorbed intestinal antimicrobial therapy.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Irritable Bowel Syndrome Therapeutic Has Broad-Spectrum Antimicrobial Activity. · full record | OpenQuestion